Biotech Values

[DewDiligence]

Based on the trial cited in your post, ABT-072 is evidently still a viable candidate. I wasn’t sure if it was because: i) ABT stopped mentioning ABT-072 by name in its PR’s; and ii) the only ABT-072 trial at clinicaltrials.gov other than the one you cited is a “resistance assessing” trial (http://clinicaltrials.gov/ct2/show/NCT00872196 ), which may be an indication that there are problems.